Kentucky 2024 Regular Session Status: In Committee 5 R cosponsors

HB 229 — AN ACT relating to gene therapy.

Last action — to Committee on Committees (H)

  1. ✓
    Introduced
  2. 2
    In Committee
  3. 3
    Passed House
  4. 4
    Passed Senate
  5. 5
    To Executive
  6. 6
    Enacted

This bill died with 2024 Regular Session. It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.

This bill is no longer active — its legislative session has ended, so there are no live odds of enactment. It would have to be reintroduced in the current session to move again.

Summary

Create a new section of KRS 217.005 to 217.215, the Kentucky Food, Drug, and Cosmetic Act, to define terms; require products that are known to be or could act as gene therapy to be labeled with the words "Potential Gene Therapy Product" or "Gene Therapy Product"; require any entity in the state that produces, sells, or distributes a product in this state with the capacity to infect an individual with a disease or to expose an individual with genetically modified material to provide information upon request on how individuals may be exposed; require informed consent before any entity makes available a product in this state that would act as a medical intervention, vaccine, drug, or genetic modification.

Bill Text

Action History

  1. to Committee on Committees (H)

  2. introduced in House

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

6 sponsors · 0 co-sponsors · 132 not signed on

Sponsors (6)

Co-sponsors (0)

None.

Not signed on (132)

132 members have not signed on to this bill.

Show all 132 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Subjects

healthcare health-insurance
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

What does HB 229 do?
Create a new section of KRS 217.005 to 217.215, the Kentucky Food, Drug, and Cosmetic Act, to define terms; require products that are known to be or could act as gene therapy to be labeled with the words "Potential Gene Therapy Product" or "Gene Therapy Product"; require any entity in the state that produces, sells, or distributes a product in this state with the capacity to infect an individual with a disease or to expose an individual with genetically modified material to provide information upon request on how individuals may be exposed; require informed consent before any entity makes available a product in this state that would act as a medical intervention, vaccine, drug, or genetic modification.
Who sponsors HB 229?
HB 229 is sponsored by Emily Callaway (Republican), Jennifer Decker (Republican), D. Bentley, John Hodgson (Republican), Marianne Proctor (Republican), and Steve Rawlings (Republican).
What is the current status of HB 229?
This bill died with 2024 Regular Session. It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
Where can I track HB 229?
Track HB 229 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on HB 229

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of HB 229

Last checked for changes 2 months ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →